FNCH Insider Trading

Insider Ownership Percentage: 44.90%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Finch Therapeutics Group Insider Trading History Chart

This chart shows the insider buying and selling history at Finch Therapeutics Group by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$10k$0$10kTotal Insider BuyingTotal Insider Selling

Finch Therapeutics Group Share Price & Price History

Current Price: $13.50
Price Change: Price Decrease of -0.65 (-4.59%)
As of 04/4/2025 04:55 PM ET

This chart shows the closing price history over time for FNCH up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$13.50Closing price on 04/05/25:

Finch Therapeutics Group Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for Finch Therapeutics Group (NASDAQ:FNCH)

21.77% of Finch Therapeutics Group stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at FNCH by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$20M$0$20MTotal InflowsTotal Outflows
Finch Therapeutics Group logo
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.
Read More on Finch Therapeutics Group

Today's Range

Now: $13.50
Low: $13.50
High: $14.00

50 Day Range

MA: $14.05
Low: $11.15
High: $15.80

52 Week Range

Now: $13.50
Low: $0.80
High: $15.85

Volume

1,689 shs

Average Volume

2,165 shs

Market Capitalization

$21.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.25

Who are the company insiders with the largest holdings of Finch Therapeutics Group?

Finch Therapeutics Group's top insider investors include:
  1. Jeffery A Smisek (Director)
  2. Jeffery A Smisek (Director)
Learn More about top insider investors at Finch Therapeutics Group.